BE Biosol, Gates Foundation to expand access to iron injection

In Short

The Gates Foundation will support the company for scaling-up and clinical development of the product for the target markets.

BE Biosol, Gates Foundation to expand access to iron injection
X

BE Biosol, Gates Foundation to expand access to iron injection

Font size
FOLLOW ON Google News

Hyderabad: Iron deficiency anaemia affects millions of people worldwide, especially in low- and middle-income countries, and access to affordable treatment remains challenging. In an important step to address this challenge, BE Biosol Private Limited, a wholly owned subsidiary of Biological E Limited, has entered into an agreement with the Gates Foundation for the development and improvement of accessibility to Ferric Carboxymaltose (FCM) injection to multiple countries.

The Gates Foundation will support the company for scaling-up and clinical development of the product for the target markets. The company will leverage its R&D capabilities and manufacturing infrastructure to support the programme. Commissioned in 2018, its manufacturing facility in Shamirpet, Telangana, has undergone multiple inspections and received approvals multiple times from leading regulatory agencies, including the USFDA, Infarmed (Portugal), the UK MHRA and Brazil’s ANVISA.

The agreement is particularly strategic for BE Biosol as the US and European FCM markets approach a transition towards generic competition.

The Hans India
ABOUT THE AUTHOR

The Hans India

Next Story
Share it